Silencing of DLC1 Upregulates PAI-1 Expression and Reduces Migration in Normal Prostate Cells

Yi-Ping Shih1,2, Yoshikazu Takada2,3, and Su Hao Lo1,2

Abstract

Deleted in liver cancer 1 (DLC1) is a GTPase-activating protein (GAP) domain containing tumor suppressor that localizes to focal adhesions. In cancer cells, loss of DLC1 is known to enhance cancer cell migration. However, the role of DLC1 in normal cell migration has not been well studied. Here, we show that silencing of DLC1 (shDLC1) in normal prostate epithelial cells reduces cell migration in both Transwell and wound-healing assays. This migration defect is mainly due to upregulation of plasminogen activator inhibitor 1 (PAI-1). Silencing of PAI-1 rescues the shDLC1-reduced migration phenotype. Reexpression of DLC1 suppresses PAI-1 and restores the migration defect as well. In contrast, DLC1-K714E (GAP inactive) mutant neither decreases the PAI-1 level nor rescues the shDLC1 migration defect. Interestingly, DLC1-Y442F (tensin-binding and focal adhesion–localizing defective) mutant is able to suppress PAI-1 expression but does not restore the migration defect. Furthermore, PAI-1 upregulation in shDLC1 cells is EGFR-MEK pathway dependent and is able to promote in vitro angiogenesis.

Together, our results show that at least the following two new mechanisms are involved in DLC1-mediated normal cell migration: (i) DLC1 modulates the expression of PAI-1, which is a negative regulator for cell migration, in a GAP domain and EGFR-MEK–dependent manner and (ii) Independent of PAI-1, the interaction of DLC1 with tensin members positively regulates cell migration.

Introduction

Deleted in liver cancer 1 (DLC1) is a focal adhesion protein that contains multiple domains including the SAM (sterile alpha motif), GAP (GTPase-activating protein), and START [steroidogenic acute regulatory (StAR)-related lipid transfer] domains. It was initially isolated as a potential tumor suppressor gene often deleted in hepatocellular carcinoma (1). Further studies have indicated that reduced expression of DLC1, either by genomic deletion or DNA methylation, is associated with a variety of cancers, including that of the prostate, lung, breast, kidney, colon, uterus, ovary, and stomach (2, 3). Mutations in DLC1 that attenuate its expression and function have been identified in prostate and colon cancer (4). The function of DLC1 has been linked to the regulation of cytoskeleton organization, cell migration, proliferation, and apoptosis (2, 3). Recently, a new role of DLC1 in modulating angiogenesis has been discovered (5), extending the understanding of its functions.

The role of DLC1 in cancer cell migration has been reported in numerous studies. Overall, ectopic expression of DLC1 suppresses breast, liver, and kidney cancer cell migration (6–8). Meanwhile, silencing of endogenous DLC1 in breast and colon cancer cells promotes migration (9, 10). The regulatory mechanism of DLC1 in cell migration as well as other cellular events has been linked to its negative regulation of the RhoA pathway through the GAP domain. RhoA is known to promote cell migration through the activation of ROCK (Rho-associated coiled-coil kinase) and mDia1 (mammalian homolog of Drosophila diaphanous) pathways (11). On the other hand, it has been shown that focal adhesion localization is also essential for the function of DLC1 in suppression of tumor cell growth (12, 13), although how this focal adhesion localization relates to migration is not known.

However, the role of DLC1 in cell migration in non-cancer cells is relatively unexplored. Therefore, the purpose of this study was to investigate the role of DLC1 in cell migration in normal prostate epithelial cells. Here, we show that silencing of DLC1 in normal cells reduces cell migration in a non-RhoA- or VEGF-dependent manner. Instead, migration is mediated through upregulation of PAI-1 (plasminogen activator inhibitor-1) and is dependent on the GAP activity of DLC1, as well as the EGFR-MEK pathway. Interestingly, reexpression of a DLC1 mutant that lacks tensin-binding activity also suppresses PAI-1 expression but does not rescue the migration defect. This indicates that
tensin binding is also essential for DLC1-mediated cell migration.

Materials and Methods

Cell culture and reagents

Stable shGFP or shDLC1 cells were generated by short hairpin RNA (shRNA) lentivirus infection and maintained in keratinocyte serum-free medium containing puromycin (2.5 μg/mL; Invitrogen) as described (5). Human umbilical vein endothelium cells (HUVEC) from American Type Culture Collection (CRL-1730) were cultured in endothelial cell growth medium (Genlantis). Human prostate epithelial cells (PrEC) from Lonza were cultured in PrEGM prostate epithelial cell growth medium (Lonza). Cells were used within 3 months after receipt or reconstituted from frozen aliquots. No additional test was done specifically for this study. PAI-1 ELISA kit (R&D Systems) was used to determine PAI-1 levels in conditioned media. The siPAI-1
5'-AAGCAGCUAGGGAAUCAAtt-3' was obtained from Ambion. The control siRNA (sc-37007), RhoA siRNA (sc-29471), VEGF siRNA (sc-29520), DLC1 siRNA (sc-43725), and anti-PAI-1 antibody (sc-5297) were purchased from Santa Cruz Biotechnology. Anti-VEGF antibody was from R&D Systems (clone 26503).

Cell migration

For the Transwell migration assay, shGFP and shDLC1 cells were trypsinized, resuspended in keratinocyte serum-free medium, and transferred to the upper chamber (1 × 10^5 cells in 200 μL); 400 μL of keratinocyte completed medium was added to the lower chamber. After incubation for 16 hours, cells on the upper surface of the filter were removed with a cotton swab and cells on the low surface were fixed, stained, and photographed.

For the wound-healing assay, cells were seeded on 6-well plates and cultured to confluence. The confluent monolayer was then wounded with a pipette tip and cells were allowed to migrate for 24 hours. Images were taken and migration distances were measured by ImageJ software (NIH).

In vitro angiogenesis tube formation assay

Growth factor–reduced Matrigel was used to coat 96-well plate (50 μL per well) and HUVECs (20,000 cells per well) were seeded with conditioned medium (200 μL). After 4 hours of incubation, capillary-like structures were scored by measuring lengths of tubules per field in each well at 100× magnification with Image J software (NIH).

Adenoviruses

A silent mutation (856cysteine: TGT to TGC) was introduced to human DLC1 cDNA in a pENTR1A vector to generate the shRNA-resistant expression construct. This DLC1/pENTR1A construct was used to generate Y442F and K714E mutants. These DLC1 inserts were moved into a pAD/CMV/V5-DEST vector by site-directed recombination reactions (Invitrogen). The adenoviral expression vectors were transfected into 293A cells. After 10 to 12 days, the crude viral lysates were harvested and used for infection.

Results

Downregulation of DLC1 in normal epithelial cells reduces cell migration

Previous studies from other groups have shown that overexpression of DLC1 in various cancer cell lines reduces cell migration and invasion (6–8), suggesting a negative regulation of DLC1 on cancer cell migration. Recently, we
established DLC1 knockdown (shDLC1) cells using two nonmalignant prostate epithelial cell lines, RWPE1 and MLC-SV40 and showed a role for DLC1 in regulating angiogenesis through VEGF expression (5). With these cell systems, we further examined the effect of loss of DLC1 on cell migration. As analyzed by *in vitro* wound-healing and Transwell migration assays (Fig. 1A and B), silencing of DLC1 in both cell lines significantly reduces cell migration. Reduction of cell migration resulting from DLC1 down-regulation by either siRNA transfection or shRNA lentivirus infection was also observed in normal primary PrECs (Fig. 1C). Because the DLC1 siRNA and shRNA targeted different regions of DLC1, the experiment also ruled out potential off-target effects.

**DLC1 negatively regulates plasminogen activator inhibitor 1 expression**

Because DLC1 suppresses RhoA GTPase activity through its GAP domain and RhoA regulates cell migration, we examined the role of RhoA in shDLC1 cell migration. Interestingly, instead of rescuing cell migration, silencing of RhoA further reduced cell migration (Fig. 2). Because VEGF was upregulated in shDLC1 cells (5), we tested whether VEGF was responsible for the migration defect in shDLC1 cells. Again, downregulation of VEGF by siRNA did not restore but further impaired migration (Fig. 2). To understand the potential mechanism involving DLC1-mediated cell migration, gene expression profiles in these cells were studied. In addition to the previously identified VEGF, the mRNA and protein levels of PAI-1 were significantly upregulated in shDLC1 cells (Fig. 3A). PAI-1 levels in the conditioned media were also increased (Fig. 3A). Because PAI-1 is known to regulate cell migration (14) and is upregulated in shDLC1 cells, we examined whether PAI-1 was the key factor in suppressing cell migration in shDLC1 cells. By silencing PAI-1 in MLC-SV40 and RWPE1 shDLC1 cells, the migration defects were rescued in both cell systems (Fig. 3B). In addition, because PAI-1 is a known proangiogenic factor, we tested the effects of shDLC1 conditioned media on endothelial tube formation in the presence of PAI1- and VEGF-neutralizing antibodies (Fig. 3C). VEGF in the conditioned media appeared to be the key angiogenic factor but PAI-1 also contributed to the tube formation. When both neutralizing antibodies were applied, the tube formation activity was reduced to baseline level.

Rescue experiments reveal PAI-1–dependent and -independent migration in shDLC1 cells

To further investigate the functional interaction among DLC1, PAI-1, and cell migration, we reexpressed various shRNA-resistant DLC1 constructs in shDLC1 cells and monitored PAI-1 expression as well as cell migration. As shown in Fig. 4, reexpression of wild-type or Y442F (tensin-binding defective) DLC1 constructs in shDLC1 cells suppressed PAI-1 levels. However, expression of K714E (GAP inactive) DLC1 mutant had no effect on reducing PAI-1

![Figure 2](image-url). Silencing of RhoA or VEGF further reduces shDLC1 cell migration. A, MLC shGFP transfected with scramble control siRNA (i) or shDLC1 treated with siRNAs for control (ii), RhoA (iii), or VEGF (iv) for 48 hours, were used for 16 hours for Transwell migration assays. B, the same experiments were carried out in RWPE1 cell system. Data are from triplicate experiments.

![Diagram](image-url)

Figure 2. Silencing of RhoA or VEGF further reduces shDLC1 cell migration. A, MLC shGFP transfected with scramble control siRNA (i) or shDLC1 treated with siRNAs for control (ii), RhoA (iii), or VEGF (iv) for 48 hours, were used for 16 hours for Transwell migration assays. B, the same experiments were carried out in RWPE1 cell system. Data are from triplicate experiments.
expression. Nonetheless, only wild-type DLC1 was able to restore cell migration in these cell lines, suggesting that DLC1 regulates cell migration through GAP domain/activity–mediated PAI-1 expression, and tensin-binding mediated pathway that is independent of PAI-1 expression. Both components are critical to the function of DLC1 in regulating cell migration.

Upregulation of PAI-1 in shDLC1 cells is EGFR-MEK pathway dependent

Because we previously found VEGF upregulation in shDLC1 cells was mediated through the EGFR-MEK pathway (5) and this pathway is also known to promote PAI-1 expression in other cell systems (15), we tested whether epidermal growth factor receptor (EGFR) and mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) activities were required for PAI-1 expression in our cell systems. Silencing of either EGFR or MEK led to downexpression of PAI-1 protein (Fig. 4C), indicating that upregulation of PAI-1 in shDLC1 cells is EGFR-MEK pathway dependent. The rescue experiments also show that the GAP domain, but not the tensin-binding domain, of DLC1 is required for suppressing EGFR and MEK activities (Fig. 4B).

Discussion

In this report, we have shown that DLC1 acts as a positive regulator on normal prostate epithelial cell migration. This positive regulation effect seemingly contradicts previous reports that have shown a negative role on cell migration. Those studies were often based on the observation that ectopic expression of DLC1 suppressed cancer cell migration (6–8) or silencing of DLC1 enhanced cancer cell migration (9, 10). The observed difference may result from the use of cancer cells versus normal cells. Cancer cell lines are known to contain various mutations and dysregulated signaling pathways, which may alter the effect of DLC1 on cancer cell migration.

Our current studies show that both GAP domain and tensin-binding activities contribute to DLC1-mediated cell migration under different mechanisms. The GAP domain is required to inactivate EGFR. Without the GAP activity of DLC1, EGFR activates its downstream signaling and enhances PAI-1 expression, which reduces normal cell migration. On the other hand, interaction with tensins and/or localization to focal adhesions is not essential for regulating EGFR activity but is required for DLC1-mediated migration. In addition to our findings, it has been reported that binding of eukaryotic elongation factor 1A1 to the SAM domain of DLC1 suppresses cell migration (16). The SAM domain also interacts with PTEN, which reduces cell migration by suppressing focal adhesion kinase activity (17).

As mentioned above, the GAP domain of DLC1 regulates PAI-1 expression through the EGFR-MEK pathway. This is in agreement with other findings showing that TGFβ1-induced PAI-1 expression requires EGFR signaling (15). However, how DLC1 suppresses EGFR activity is currently not clear. It is known that deformation of cytoskeleton activates receptor tyrosine kinases, such as EGFR, leading to PAI-1 expression (18, 19). It is possible that DLC1 represses a yet-to-be-identified small GTPase that regulates cytoskeleton networks. Lack of DLC1 activates this GTPase, which reorganizes cytoskeleton leading to EGFR activation. We are currently testing this possibility.
The finding of PAI-1 regulated by DLC1 suggests that DLC1 may participate in fibrinolysis, which plays a critical role in dissolution of blood fibrin clots (20). Plasminogen is cleaved into the active form plasmin by plasminogen activators (either tissue-type or urokinase-type), which are negatively regulated by PAI-1. Plasmin then degrades fibrin into soluble fibrin degradation products that are removed by other proteases or by the kidney and liver. Interestingly, a recent report showed a direct interaction between DLC1 and p11 (a.k.a. S100A10 or annexin 2 light chain) and this binding promoted p11 protein degradation, which attenuated plasminogen activation (21). Therefore, DLC1 negatively regulates both PAI-1 and p11 protein levels, leading to opposite effects on plasminogen activation. How these two mechanisms coordinate within the process remains to be investigated.

Because PAI-1 is also involved in obesity, diabetes, inflammation, and renal injury (20), the role of DLC1 in these conditions warrants more attention.

Recently, we have shown that DLC1 negatively regulates angiogenesis by suppressing VEGF expression in epithelial cells. Our current finding has added the regulation of PAI-1, another proangiogenic factor, to the equation and further strengthens the function of DLC1 in regulating angiogenesis. Furthermore, we have identified a novel role of DLC2, another family member, by showing enhanced angiogenic response in DLC2-null endothelial cells and null mice (22). Altogether, these findings indicate that DLC1 and DLC2 regulate angiogenesis through distinct mechanisms in various cell types.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

The work was supported by NIH (grants CA102537 and CA151366) to S.H. Lo. Y.-P. Shih is a T32 fellowship recipient (T32CA108459).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 15, 2011; revised October 31, 2011; accepted November 2, 2011; published OnlineFirst November 7, 2011.

References


Shih et al.

Silencing of DLC1 Upregulates PAI-1 Expression and Reduces Migration in Normal Prostate Cells

Yi-Ping Shih, Yoshikazu Takada and Su Hao Lo

Mol Cancer Res  Published OnlineFirst November 7, 2011.

Updated version  Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-11-0450

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.